SCHEMBL13243993

SCHEMBL13243993

Cc1cccc(N2CCN(C)CC2)c1C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.65
ALDH1A1 P00352 6/20 0.62
NPSR1 Q6W5P4 2/20 0.62
TSHR P16473 3/20 0.60
MAPK1 P28482 1/20 0.60
KMT2A Q03164 4/20 0.59
MEN1 O00255 3/20 0.59
LMNA P02545 3/20 0.57
HPGD P15428 2/20 0.57
GAA P10253 1/20 0.57
MAPT P10636 4/20 0.55
DRD2 P14416 1/20 0.55
DRD3 P35462 1/20 0.55
ADRA2C P18825 1/20 0.53
KDM4E B2RXH2 2/20 0.53
ALOX15 P16050 1/20 0.53
HSD17B10 Q99714 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11067105 0.92 ADRB1 (0.74) ADRB1ALDH1A1NPSR1TSHRMAPK1
SCHEMBL30656303 0.83 ADRB1 (0.62) ADRB1ALDH1A1MAPK1KMT2ALMNA
SCHEMBL23843550 0.83 ADRB1 (0.69) ADRB1ALDH1A1NPSR1TSHRMAPK1
SCHEMBL29058159 0.83 ADRB1 (0.69) ADRB1ALDH1A1NPSR1TSHRMAPK1
SCHEMBL173027 0.83 ADRB1 (0.62) ADRB1ALDH1A1MAPK1KMT2ALMNA
SCHEMBL9065218 0.82 LMNA (0.68) ADRB1ALDH1A1NPSR1TSHRMAPK1
SCHEMBL30228454 0.82 LMNA (0.68) ADRB1ALDH1A1NPSR1TSHRMAPK1
SCHEMBL8894088 0.82 LMNA (0.68) ADRB1ALDH1A1NPSR1TSHRMAPK1
Ammonia Solution, Strong SCHEMBL28721086 0.82 ADRB1 (0.60) ADRB1ALDH1A1MAPK1KMT2ALMNA
SCHEMBL3555024 0.81 ADRA2C (0.59) ALDH1A1MAPK1KMT2ALMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3250209-B1 COMT INHIBITING METHODS AND COMPOSITIONS LIEBER INST FOR BRAIN DEVELOPMENT (US) 2023-09-13 EP disclosed
US-10479790-B2 COMT inhibiting methods and compositions LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) 2019-11-19 US disclosed
US-10035799-B2 COMT inhibiting methods and compositions LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) 2018-07-31 US disclosed
US-9598361-B1 Amino substituted acetamide derivative KING SAUD UNIVERSITY (SA) 2017-03-21 US disclosed
US-9598361-B1 Amino substituted acetamide derivative KING SAUD UNIVERSITY (SA) 2017-03-21 US disclosed
US-20160222011-A1 COMT Inhibiting Methods and Compositions LIEBER INSTITUTE, INC. 2016-08-04 US disclosed
WO-2013023273-A1 PIPERAZINE DERIVATIVES ST. MARY'S UNIVERSITY (CA) 2013-02-21 WO disclosed
EP-1322622-B1 NEW N, N'-DISUBSTITUTED BENZIMIDAZOLONE DERIVATIVES WITH AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS SPROUT PHARMACEUTICALS INC (US) 2012-10-31 EP disclosed
US-7772190-B2 Didepsipeptide-based endoparasiticides, new didepsipeptides and process for preparing the same BAYER ANIMAL HEALTH GMBH (DE) 2010-08-10 US disclosed
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility UNIVERSITA DEGLI STUDI DI SIENA (IT) 2009-09-24 US disclosed
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility UNIVERSITA DEGLI STUDI DI SIENA (IT) 2009-09-24 US disclosed
EP-0819000-B1 NODULISPORIC ACID DERIVATIVES MERCK & CO INC (US) 2009-07-08 EP disclosed
US-7220765-B2 Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) 2007-05-22 US disclosed
US-20070043095-A1 Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use IPSEN PHARMA S.A.S. (FR) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043095-A1 Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use SSTR2, SSTR5, SSTR3 ADRB1 58/4885ALDH1A1 812/4885NPSR1 31/4885
US-10035799-B2 COMT inhibiting methods and compositions COMT, SLC6A3, MAOA ADRB1 170/4885ALDH1A1 79/4885NPSR1 1195/4885
US-20160222011-A1 COMT Inhibiting Methods and Compositions COMT, SLC6A3, MAOA ADRB1 170/4885ALDH1A1 79/4885NPSR1 1195/4885
US-10479790-B2 COMT inhibiting methods and compositions COMT, SLC6A3, MAOA ADRB1 170/4885ALDH1A1 79/4885NPSR1 1195/4885
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility HTR2C, HTR2A, DRD2 ADRB1 199/4885ALDH1A1 1390/4885NPSR1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.